|Awarded On||March 29, 2012|
|Title||Formation of The Texas Cancer Therapeutics Process Development Lab|
|Program||Product Development Research|
|Award Mechanism||Company Formation|
|Institution/Organization||Fujifilm Diosynth Biotechnologies Texas, LLC.|
|Principal Investigator/Program Director||Gerry Farrell|
|Cancer Sites||All Sites|
The development of cancer drugs in the future mandates innovation. Central to that innovation in Texas is the ability to advance drug discovery to clinical trial scale up. Texas’ preeminent cancer research institutes and biotech companies are often stymied in development of their discoveries due to the inability to scale up the drug for clinical trials and commercial launch. While renowned for its discoveries, Texas offers little manufacturing capability.
In 2009, the State, through the Emerging Technology Fund, sought to fill this need by funding The Texas A&M University System to construct The National Center for Therapeutics Manufacturing (NCTM), a multi-product, flexible-by-design drug ...